Seeking Alpha

Results from a Phase II trial of a cholestoral drug from Regeneron (REGN +0.7%) were good but...

Results from a Phase II trial of a cholestoral drug from Regeneron (REGN +0.7%) were good but were upstaged at a heart conference by the outcome of a Phase I trial of a rival treatment from Amgen (AMGN +1.5%), which was better. Still, both drugs have a long way to go before they'll be able to enter a market that could be worth $20B/year.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs